Section 3 of 6
Product information and disease description
276 evidence topics · 92 sources
Product description
Phase of product development
Summary: development and regulatory status as of November 2026
Vorolanib intravitreal insert (DURAVYU, EYP-1901) is an investigational product and is not approved by the FDA; the FDA has conditionally accepted DURAVYU as its proprietary name. Two identical randomized, double-masked phase 3 non-inferiority trials, designed with feedback from the FDA and the European Medicines Agency, compared vorolanib intravitreal insert 2.7 mg every 6 months with on-label aflibercept 2 mg: LUGANO enrolled 432 participants and LUCIA enrolled 475 participants. On August 17, 2026, EyePoint reported that LUGANO did not meet its primary endpoint (mean change in best-corrected visual acuity, blended weeks 52 and 56) in the full dataset. In an ad hoc analysis that excluded 9 of 211 participants (4%) in the vorolanib insert arm who lost 15 or more letters from causes the sponsor attributed to conditions other than wet AMD, the sponsor reported non-inferiority with a nominal p-value of 0.0096. After LUGANO, the sponsor planned a pre-NDA meeting in the fourth quarter of 2026 and an NDA submission in the first half of 2027, provided that LUCIA results were positive; the NDA was to contain the initial 56-week efficacy and safety data, with year 2 safety data in a supplemental NDA. On October 19, 2026, EyePoint reported that LUCIA also did not meet the primary endpoint (least squares mean BCVA change +2.5 letters with the vorolanib insert and +6.1 letters with aflibercept; difference -3.7 letters), announced that it would conclude both phase 3 wet AMD trials early, without full completion of the second year of each trial, and stated that it would prioritize development in diabetic macular edema. In its third quarter 2026 results of November 12, 2026, EyePoint stated that it will conclude the wet AMD program before completion of the full second year of LUGANO and LUCIA, while allowing additional participants to complete year two to support the safety database for a potential NDA in diabetic macular edema, and that it will complete additional analyses of the LUGANO, LUCIA, and pooled phase 3 datasets to assess next steps in wet AMD. As of November 2026, EyePoint has announced no NDA submission for wet AMD and no launch timing, and no Fast Track, Breakthrough Therapy, or Priority Review designation was identified. Two phase 3 trials in diabetic macular edema (COMO and CAPRI) completed enrollment of more than 480 participants in five months, with topline data expected in the fourth quarter of 2027.
Investigational status and conditionally accepted proprietary name
Phase 3 wet AMD program: design and enrollment
LUGANO topline result: primary endpoint
LUCIA readout and planned NDA submission
Regulatory strategy after LUGANO and after LUCIA
Planned content of the NDA and supplemental NDA
Diabetic macular edema phase 3 program
Expedited program designations (Fast Track, Breakthrough Therapy, or Priority Review)
No evidence found.
Regulatory status: No submission planned; Phase 3 trials in wet AMD ending early after LUCIA missed its primary endpoint in October 2026
“WATERTOWN, Mass., November 12, 2026 (GLOBE NEWSWIRE)” (opens the source at this quote in a new tab)
Launch
No evidence found.
Product information
Generic, brand name and therapeutic class of product
Established name, proprietary name, and development code
Therapeutic class and delivery technology
Manufacturer: EyePoint
Dosage forms and strengths
Phase 3 dose: two inserts in one injection
Phase 3 dose as registered
| Field | Quoted record |
|---|---|
| Experimental arm | “EYP-1901 2686 µg” |
| Route | “Intravitreal Injection” |
Insert composition
Storage conditions in clinical trials
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
Mechanistic classification: type II pan-VEGFR tyrosine kinase inhibitor
“Our modeling results predict that vorolanib strongly binds intracellularly near the ATP binding regions of VEGFR1, VEGFR2, and VEGFR3 when the VEGFRs are in the DFG-out (inactive) configuration, making vorolanib a type II pan-VEGFR inhibitor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prior approval of oral vorolanib outside ophthalmology
AHFS classification
No evidence found.
Indication
Population studied in the phase 3 wet AMD trials
Label scope sought by the sponsor
Other indication in development: diabetic macular edema
Pharmacology
Mechanism of action
Receptor-level blockade of VEGF signaling
ATP-competitive inhibition of VEGFR-1, -2, and -3
“potently inhibits all 3 VEGFRs (VEGFR-1, -2, and -3; manuscript in preparation) by competing with adenosine triphosphate for binding to the tyrosine kinase domain of VEGFR inside the cell membrane.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Vorolanib would therefore be expected to inhibit most VEGF pathway signaling, perhaps to a greater degree than current anti-VEGF drugs that each target only 1 form of VEGF and leave VEGFRs available to be activated by other forms of VEGF.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selectivity against TIE2 compared with other TKIs
“Vorolanib, sunitinib, and axitinib exhibited pan-VEGFR inhibition and inhibited RTKs associated with pathological angiogenesis. Of the three TKIs, only axitinib potently inhibited TIE2 which is an undesired trait as TIE2 is essential for vascular stability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sustained delivery through the bioerodible Durasert E insert
Class mechanism and differences in receptor selectivity among VEGFR tyrosine kinase inhibitors
“Tyrosine kinase inhibitors (TKIs) are small molecules that act at the intracellular level to inhibit receptor tyrosine kinase by preventing tyrosine kinase phosphorylation and the downstream signaling cascade.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, TKIs are capable of inhibiting all isoforms of VEGF as well as other receptor tyrosine kinases including fibroblast growth factor receptor and platelet-derived growth factor receptor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In vitro, individual TKIs differ in their VEGFR-binding affinity, receptor selectivity profiles, and off-target inhibition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These differences in molecular selectivity may influence not only efficacy and durability but also safety profiles when these agents are applied to ocular tissues via sustained-release platforms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Preclinical: VEGFR2 inhibitory concentration
Preclinical: angiogenesis and melanin binding
“All three TKIs effectively inhibited angiogenesis in vitro. In vivo, TKIs were more effective at inhibiting VEGF-induced angiogenesis than the anti-VEGF antibody bevacizumab. Of the three TKIs, only sunitinib bound melanin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical: IL-6 signaling and neuroprotection
Preclinical: time to target tissue concentrations in rabbits
Preclinical: oral vorolanib in choroidal and retinal neovascularization models
“Oral X-82 was found to inhibit Matrigel-induced choroidal neovascularization in a rat model.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An oxygen-induced ischemic retinopathy mouse model also showed potent inhibition of retinal neovascularization, with cell culture studies suggesting similar antiangiogenic activity to sunitinib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics
Summary: systemic and aqueous humor exposure in DAVIO 2
In the phase 2 DAVIO 2 trial, a single vorolanib insert dose (2,060 µg or 3,090 µg) was given at week 8. Mean plasma vorolanib concentrations were 0.000 pg/mL at week 8 (the visit at which the insert was administered), 23.206 pg/mL (2,060 µg; 46 participants) and 27.121 pg/mL (3,090 µg; 47 participants) at week 20, and 7.733 pg/mL (45 participants) and 10.392 pg/mL (50 participants) at week 56. Mean aqueous humor concentrations at week 20 were 17.426 ng/mL (43 participants) and 25.066 ng/mL (49 participants). Plasma concentrations were reported in picograms per milliliter and aqueous humor concentrations in nanograms per milliliter. Mean plasma concentrations of the main metabolite did not exceed 2.46 pg/mL at any sampled visit.
Release duration by design
Preclinical release kinetics in rabbits
“In rabbit studies, the EYP-1901 insert showed a burst in drug release that rapidly resulted in steady-state levels in ocular tissues with an average zero-order drug-release rate of approximately 8% of the total dose per month through 8 months; this was followed by a rapid decrease through 10 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical ocular and plasma concentrations in rabbits
“Findings showed that EYP-1901 was able to reach steady state quickly in all locations and this was maintained until depletion of the drug around 240–270 days after insert. The main targets of retina and choroid maintained a VEGFR2 IC50 of above 23 ng/ml through day 240 while plasma and aqueous humor levels were consistently below 23 ng/ml” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the insert measurements, the 643 μg insert showed a release rate of 1.73 μg per day while the 2 inserts of 900 μg showed a release rate of 2.33 μg per day” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
DAVIO 2: plasma vorolanib concentrations (pg/mL) after a single insert dose at week 8
Pharmacokinetics after repeat dosing every 6 months
No evidence found.
Vitreous clearance of tyrosine kinase inhibitors and the rationale for sustained release
“Rapid vitreous clearance of existing VEGF inhibitors limits durability to 1-4 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“TKIs are small molecules and rapidly cleared from the vitreous.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Combining TKIs with sustained release platforms, such as hydrogel or polyvinyl alcohol, allow for the sustained release of the molecules and the potential for extended durability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The implant is designed to release vorolanib at near zero order kinetics for 9 months and to be completely bioerodible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Summary: safety in LUGANO through week 56
Through week 56 of LUGANO, the ocular adverse events in the study eye with the largest absolute differences between vorolanib intravitreal insert 2.7 mg (211 participants) and aflibercept 2 mg (221 participants) were conjunctival haemorrhage (11.4% and 5.0%), vitreous floaters (9.0% and 3.6%), and neovascular age-related macular degeneration (7.1% and 1.4%). Intraocular inflammation (0.5% in each arm) and retinal detachment (0.5% in each arm) were infrequent, and the sponsor reported no cases of insert migration into the anterior chamber, retinal vasculitis, or severe intraocular inflammation. Nine participants (4%) in the vorolanib insert arm lost 15 or more letters from causes attributed by the sponsor to geographic atrophy (6), glaucoma (2), or retinal detachment (1); no participant in the aflibercept arm had such a loss. These data are preliminary and pending final analysis.
FDA-approved prescribing information, contraindications, boxed warnings, and REMS
Not applicable.
LUGANO: ocular adverse events in the study eye (≥2%) through week 56
| Adverse event | DURAVYU 2.7 mg (n=211) | Aflibercept 2 mg (n=221) |
|---|---|---|
| Conjunctival haemorrhage | “11.4%” | “5.0%” |
| Vitreous floaters | “9.0%” | “3.6%” |
| Neovascular age-related macular degeneration | “7.1%” | “1.4%” |
| Retinal haemorrhage | “4.7%” | “1.8%” |
| Vitreous detachment | “4.7%” | “4.1%” |
| Cataract | “4.3%” | “5.4%” |
| Dry eye | “4.3%” | “6.3%” |
| Posterior capsule opacification | “4.3%” | “2.3%” |
| Intraocular pressure increased | “3.8%” | “3.2%” |
| Visual acuity reduced | “3.8%” | “5.4%” |
| Retinal oedema | “2.8%” | “0.9%” |
| Visual impairment | “2.4%” | “0.0%” |
| Dry age-related macular degeneration | “2.4%” | “3.2%” |
| Eye pain | “2.4%” | “0.9%” |
| Subretinal fluid | “2.4%” | “1.4%” |
LUGANO: adverse events of particular interest and discontinuations
LUGANO: vision loss of 15 or more letters not attributed to wet AMD
Phase 2 DAVIO 2: selected ocular adverse events in the study eye through week 56
Phase 1 DAVIO: ocular events not observed after a single dose
“There were no vitreous floaters, endophthalmitis, retinal detachment, insert migration into the anterior chamber, retinal vasculitis, posterior or anterior segment inflammation, vascular occlusive events, or ischemic optic neuropathy observed throughout the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Oral vorolanib: systemic adverse events in the APEX trial
“The APEX Trial was stopped prematurely due to gastrointestinal and hepatobiliary AEs associated with oral vorolanib use such as elevated liver enzymes, and due to the fulfillment of the primary endpoint (noninferiority to placebo).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Class labeling for intravitreal VEGF inhibitors (aflibercept 8 mg)
Oral vorolanib: timing and reversibility of liver enzyme elevations
“Most of the elevations occurred within 8–10 weeks of randomisation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most commonly, liver enzymes returned to normal within a few weeks after discontinuation of X-82, although some patients required several months to return to baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, all elevations returned to baseline and there were no accompanying elevations of bilirubin or alkaline phosphatase.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Oral vorolanib: transaminase elevation on rechallenge and liver function monitoring
“An asymptomatic 71-year-old woman receiving 100-mg daily had an ALT level 3.1 times the ULN and an AST level 2.7 times the ULN at month 3. X-82 was withheld, and both normalized within 3 weeks. After rechallenging with 100 mg daily, the ALT level rose to 1.6 times the ULN, and the AST level to 1.5 times the ULN. X-82 was discontinued and transaminases normalized.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The transaminase elevations did not appear to be dose related, and thus, it is important to monitor liver function in all patients receiving X-82 regardless of dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Special populations
Older adults: LUGANO baseline age
| Characteristic | DURAVYU 2.7 mg (n=211) | Aflibercept 2 mg q8W (n=216) |
|---|---|---|
| Age (years), mean (SD) | “77.5 (7.52)” | “77.0 (7.61)” |
| Age ≥ 65, n (%) | “202 (95.7)” | “205 (94.9)” |
| Female, n (%) | “136 (64.5)” | “141 (65.3)” |
Pregnancy, lactation, and contraception
Cardiovascular, bleeding, and metabolic exclusion criteria (phase 2)
Pediatric use, hepatic impairment, and renal impairment
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on vorolanib intravitreal insert
Protocol restrictions on prior and concomitant therapies (phase 2)
Clinical drug interaction studies
No evidence found.
Concomitant atorvastatin withheld with oral vorolanib during transaminase elevation
“An asymptomatic 69-year-old woman receiving 200 mg daily had an ALT level 8.4 times the ULN and an AST level 2.9 times the ULN at month 2. X-82 and atorvastatin were withheld.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By month 3, the ALT level was 1.6 times the ULN and the AST level 1.1 times the ULN, and she was rechallenged with 100 mg of X-82 daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effects of vorolanib intravitreal insert on other drugs
Clinical drug interaction studies
No evidence found.
Dosing and administration
Dosage
Summary: phase 3 dosing regimen
In LUGANO and LUCIA, all participants received scheduled aflibercept 2 mg from day 1 through week 8. Participants randomized to vorolanib intravitreal insert received 2.7 mg (two inserts in a single injection) at week 8 and were redosed every 6 months (every 24 weeks), with the second dose at week 32 and the third planned dose at week 56, for a total of four doses over the 2-year trials. Supplemental aflibercept was permitted in both arms when protocol criteria were met. EyePoint stated on November 12, 2026, that it will conclude the wet AMD program before completion of the full second year of LUGANO and LUCIA.
Phase 3: dose and redosing interval
Administration
Pre-loaded applicator and 22-gauge needle (phase 2)
Injector performance in phase 1 and further injector development
“Investigators experienced difficulties with the injector related to the advancement of the plunger as it pushed the 3 inserts (1030 μg each) through the needle.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The injector issues that caused the deviation have been resolved in the subsequent phase II DAVIO 2 trial, and the device continues to be in development.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Needle gauge and injector used in phase 3
No evidence found.
Access and distribution
Commercial manufacturing facility and registration batches
Supply chain for drug substance and injector components
FDA warning letter concerning the Watertown facility
Anticipated launch preparation and federal pricing programs
Distribution channel, specialty distribution, and patient support programs
No evidence found.
Co-prescribed/Concomitant therapies
Phase 3: aflibercept loading doses before the first vorolanib insert dose
LUGANO: supplemental aflibercept use in the vorolanib insert arm
Phase 2 DAVIO 2: aflibercept co-administration and rescue therapy
Effect of vorolanib intravitreal insert on quality measures
No evidence found.
Product comparison
Summary: dosing and administration of vorolanib intravitreal insert compared with approved therapies
In the phase 3 program, vorolanib intravitreal insert 2.7 mg is given by in-office intravitreal injection every 6 months after aflibercept loading, and it requires no cold storage. Approved labeling for aflibercept 2 mg recommends monthly injections for 3 months followed by injections every 8 weeks. Aflibercept 8 mg is given monthly for 3 doses followed by every 8 to 16 weeks, with extension to every 20 weeks considered after 1 year of successful response. Faricimab is given monthly for 4 doses followed by one of three regimens with intervals of up to 16 weeks. Ranibizumab 0.5 mg is given monthly, with less frequent regimens described as not as effective. The ranibizumab port delivery system is refilled every 24 weeks but requires surgical implantation in an operating room and carries a boxed warning for endophthalmitis. The sustained-release TKI axitinib intravitreal hydrogel (AXPAXLI) is investigational; its sponsor plans an NDA submission in the fourth quarter of 2026. No head-to-head trials of vorolanib intravitreal insert against aflibercept 8 mg, faricimab, ranibizumab, the port delivery system, or axitinib intravitreal hydrogel were identified; the phase 3 comparator was aflibercept 2 mg every 8 weeks.
Sponsor description of approved wet AMD therapies
Aflibercept 2 mg: labeled dosing in wet AMD
Aflibercept 8 mg: labeled dosing in wet AMD
Ranibizumab 0.5 mg: labeled dosing in wet AMD
Ranibizumab port delivery system: labeled dosing, surgical requirement, and boxed warning
Axitinib intravitreal hydrogel (AXPAXLI): formulation and development status
Axitinib intravitreal hydrogel (AXPAXLI): SOL-1 and SOL-R designs and SOL-1 results
Novel retinal delivery therapies: published comparison table
| Product | Mechanism of action | Duration of action | Phase of development |
|---|---|---|---|
| Vorolanib insert (EYP-1901) | “TKI: inhibition of all isoforms of VEGFR and PDGFR”View highlighted excerpt for this quote | “Six months or longer”View highlighted excerpt for this quote | “Phase 3”View highlighted excerpt for this quote |
| Axitinib hydrogel insert (OTX-TKI) | “TKI: VEGFR-1, VEGFR-2, VEGFR-3 inhibition”View highlighted excerpt for this quote | “Six months or longer”View highlighted excerpt for this quote | “Phase 3”View highlighted excerpt for this quote |
| Ranibizumab port delivery system | “VEGF-A inhibition”View highlighted excerpt for this quote | “Up to 24 weeks”View highlighted excerpt for this quote | “FDA approved”View highlighted excerpt for this quote |
| Tarcocimab tedromer (KSI-301) | “VEGF-A, VEGF-B, PIGF inhibition”View highlighted excerpt for this quote | “Up to six months”View highlighted excerpt for this quote | “Phase 3”View highlighted excerpt for this quote |
Sponsor-described differentiation from other sustained-delivery products
Head-to-head comparisons with aflibercept 8 mg, faricimab, ranibizumab, the port delivery system, or axitinib intravitreal hydrogel
No evidence found.
Axitinib intravitreal hydrogel (OTX-TKI): phase 1b rescue-free proportion and visual acuity at week 52
“By week 48, 67% of AXPAXLI-treated patients remained rescue-free, but this declined to 33% by week 52, suggesting a waning therapeutic effect near the end of the implant’s duration of action.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was an 89% reduction in anti-VEGF treatment burden at week 52 in the OTX-TKI arm.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean change in BCVA at week 52 was –1.0 (6.0) letters in the OTX-TKI group and +2 (7.2) letters in the aflibercept group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sunitinib microparticle depot (GB-102): dose discontinued for anterior chamber migration and program discontinued
“After an interim safety analysis, the 2-mg GB-102 dose was discontinued after the initial dose because of a higher incidence of AEs. These AEs included anterior chamber microparticle migration and associated visual impairment and IOP elevation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary end point, median time to first supportive therapy, was 5 months in the 1-mg group. Moreover, 62% and 48% of patients did not require supportive therapy for at least 4 and 6 months, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At this time, the sponsor has discontinued further investigation of GB-102.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Independent review: relative position of sustained-delivery platforms and uncertainty about pan-VEGF inhibition
“Intravitreal agents such as OTX-TKI and EYP-1901 have demonstrated encouraging durability and safety profiles in early-phase trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Approaches like suprachoroidal CLS-AX may offer targeted posterior segment drug delivery with reduced anterior segment and systemic exposure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among these emerging therapies, platforms combining intravitreal sustained-release technology with pan-VEGF inhibition (eg, EYP-1901, OTX-TKI, CLS-AX) currently appear the most balanced in terms of efficacy, safety, and durability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the clinical value of pan-VEGF inhibition remains uncertain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Faricimab phase 3 trials: durability not compared with extended-interval aflibercept
“one limitation of the TENAYA and LUCERNE trials is the lack of direct comparison of durability of faricimab relative to the standard of care because the comparator in these studies was administered according to a fixed 8-week dosing regimen” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The registrational phase 3 trials of faricimab for nAMD were not designed for head-to-head comparison of faricimab’s durability versus aflibercept because extended fixed 12-week or fixed 16-week dosing regimens have not been studied in double-masked phase 3 registrational trials for aflibercept.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aflibercept 8 mg: injections through week 48 and limits of direct comparison with aflibercept 2 mg
“Patients who completed the week 48 visit received a mean of 6·1 injections in the aflibercept 8q12 group, 5·2 injections in the 8q16 group, and 6·9 injections in the 2q8 group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The limitations of this study included the inability for direct comparison at several timepoints between the aflibercept 8 mg and 2 mg groups after week 16 due to the different dosing regimens.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place of product in therapy
Disease description
Definition and etiology
Summary: definition, etiology, and risk factors
Wet (neovascular) age-related macular degeneration (AMD) is the late-stage form of AMD in which abnormal blood vessels (macular neovascularization, historically called choroidal neovascularization) grow beneath or into the macula. The American Academy of Ophthalmology (AAO) estimates that about 80% of people with AMD have the non-neovascular form, while the neovascular form accounts for most of the severe vision loss. Unmodifiable risk factors are increasing age, Northern European ancestry, and genetic factors; cigarette smoking is the principal modifiable risk factor. In the Global Burden of Disease Study 2021, tobacco accounted for 9.96% of age-standardized disability-adjusted life-years attributed to AMD.
Wet AMD as the neovascular late stage of AMD
Guideline disease definition and advanced AMD classification
Risk factors: age, ancestry, genetics, and smoking
Risk factors: patient-facing summary
Tobacco-attributable burden of AMD vision impairment
Epidemiology
Incidence of Wet age-related macular degeneration
Summary: incidence
In a Bayesian meta-analysis of cohort studies in populations of European ancestry, the annual incidence of neovascular AMD in White US adults aged 50 years or older was 1.8 per 1,000, and the incidence of any late AMD was 3.5 per 1,000 (about 293,000 new cases per year). A US cost-benefit analysis estimated 168,400 new-onset neovascular AMD cases in 2018. In the Beaver Dam Eye Study (3,917 participants), the 15-year cumulative incidence of exudative AMD was 4.4% in participants aged 75 years or older at baseline and 0.4% in those aged 43 to 54 years.
Annual incidence in White US adults: meta-analysis
“Annual incidence (estimated from prevalence) of late AMD in American whites was 3.5 per 1000 aged ≥50 years (95% credible interval 2.5, 4.7 per 1000), equivalent to 293 000 new cases in American whites per year (95% credible interval 207 000, 400 000). Incidence rates approximately quadrupled per decade in age. Annual incidence GA rates were 1.9 per 1000 aged ≥50 years, NVAMD rates were 1.8 per 1000.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
New-onset neovascular AMD cases in the United States, 2018
Beaver Dam Eye Study: 15-year cumulative incidence
“The 15-year cumulative incidence was 14.3% for early AMD (the presence of either soft indistinct drusen or the presence of pigmentary abnormalities together with any type of drusen) and 3.1% for late AMD (presence of exudative AMD or geographic atrophy).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals > or = 75 years of age at baseline had significantly (P<0.01) higher 15-year incidences of the following characteristics than people 43 to 54 years of age: larger drusen (125 mum in diameter, 24.1% vs 10.6%), soft indistinct drusen (18.7% vs 6.5%), retinal pigmentary abnormalities (20.2% vs 3.7%), exudative macular degeneration (4.4% vs 0.4%), and pure geographic atrophy (3.2% vs 0%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Neovascular AMD in the fellow eye: untreated cohorts
Progression to advanced AMD in the fellow eye
Annual incidence and number of new neovascular AMD cases in White US adults
“The corresponding rates for GA and NVAMD are 1.9 per 1000 (95% credible interval 1.3, 2.8) and 1.8 per 1000 (95% credible interval 1.2, 2.5), respectively (Table 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This corresponds to approximately 293 000 new cases of late AMD each year (95% credible interval 207 000, 400 000), and 160 000 (95% credible interval 107 000, 234 000) and 148 000 (95% credible interval 103 000, 207 000) for GA and NVAMD, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although our overall estimates of NVAMD incidence are high (owing to the inclusion of those at older ages, especially in women), this does not reflect the number in need of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, the inclusion of older ages in our estimates may include a large number who are unwilling or too frail to undergo treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Neovascular AMD incidence by age: 65 years or older and 80 years or older
“In those aged 65 years and older the annual incidence rate for late AMD is 7.8 per 1000 (95% credible interval 5.5, 10.6), 4.3 per 1000 for GA (95% credible interval 2.9, 6.2), and 3.9 per 1000 for NVAMD (95% credible interval 2.7, 5.5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In those aged 80 years and older the annual incidence rates per 1000 are 19.4 (95% credible interval 13.8, 26.2), 10.9 (95% credible interval 7.2, 16.1), and 9.9 (95% credible interval 6.8, 14.0), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A meta-analysis of incidence studies showed that the incidence rate for late AMD triples per decade increase in age (rate ratio 2.9; 95% credible interval 2.6, 3.2, Table 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although late AMD incidence increases log-linearly with age, the absolute number of incident cases of late AMD decreases beyond the age of about 85 years because of increased mortality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Neovascular AMD incidence by sex
“Incidence rates for late AMD were 38% higher in women than in men (rate ratio 1.4, 95% credible interval 1.1, 1.8).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For all age groups (except the youngest), women have a slightly higher annual incidence rate of late AMD (4 per 1000, 95% credible interval 2.3, 6.6) than men (2.4 per 1000, 95% credible interval 1.4, 4.2; Table 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In those aged 65 years and older the incidence rates of NVAMD within each 5-year age group are higher in women than in men.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Under 70 years of age the number of incident cases is similar in men and women.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Fellow-eye incidence: effect of outlier studies
“These cumulative incidence rates were influenced by significant heterogeneity in the studies caused by outliers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If outliers were not included in the analysis, the 12-month incidence rate changed considerably, from 12.2% to 8.1% (95% CI, 4.9-11.9).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Excluding these outliers from the analysis reduced the 12-month incidence rate changes considerably, from 12.2% to 8.1% (95% CI, 4.9%-11.9%), which is lower than the approximately 12% per year rate reported by other single studies in the literature.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Wet age-related macular degeneration
Summary: prevalence
In a Bayesian meta-regression for 2019 using CDC Vision and Eye Health Surveillance System data, an estimated 1.49 million US adults aged 40 years or older (crude prevalence 0.94%) had late-stage AMD (choroidal neovascularization and/or geographic atrophy) and 18.34 million had early-stage AMD. The 2004 Eye Diseases Prevalence Research Group estimate was 1.75 million US adults with neovascular AMD and/or geographic atrophy (1.47%). No recent US estimate specific to the neovascular subtype was retrieved. Globally, the pooled prevalence of late AMD in people aged 45 to 85 years was 0.37% and of any AMD 8.69%, with 196 million people projected to have AMD in 2020 and 288 million in 2040.
United States, 2019: early- and late-stage AMD
“For 2019, we estimated that there were 18.34 million people 40 years and older (95% uncertainty interval [UI], 15.30-22.03) living with early-stage AMD, corresponding to a crude prevalence rate of 11.64% (95% UI, 9.71-13.98). We estimated there were 1.49 million people 40 years and older (95% UI, 0.97-2.15) living with late-stage AMD, corresponding to a crude prevalence rate of 0.94% (95% UI, 0.62-1.36).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“late-stage (defined as choroidal neovascularization and/or geographic atrophy in either eye)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States, 2000: neovascular AMD and/or geographic atrophy
“The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% (95% confidence interval, 1.38%-1.55%), with 1.75 million citizens having AMD. The prevalence of AMD increased dramatically with age, with more than 15% of the white women older than 80 years having neovascular AMD and/or geographic atrophy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: guideline summary and projection
Global prevalence: meta-analysis of 39 population-based studies
“Analysis of 129,664 individuals (aged 30-97 years), with 12,727 cases from 39 studies, showed the pooled prevalence (mapped to an age range of 45-85 years) of early, late, and any age-related macular degeneration to be 8.01% (95% CrI 3.98-15.49), 0.37% (0.18-0.77), and 8.69% (4.26-17.40), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The projected number of people with age-related macular degeneration in 2020 is 196 million (95% CrI 140-261), increasing to 288 million in 2040 (205-399).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global vision impairment due to AMD, 1990 to 2021 and forecast to 2050
“Globally, the number of individuals with vision impairment due to AMD more than doubled, rising from 3·64 million (95% uncertainty inverval [UI] 3·04–4·35) in 1990 to 8·06 million (6·71–9·82) in 2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By 2050, the number of individuals affected by AMD is projected to increase from 3·40 million males (95% UI 2·81–4·17) in 2021 to 9·02 million (5·72–14·20) and from 4·66 million females (3·88–5·65) to 12·32 million (8·88–17·08).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Late-stage AMD prevalence by sex and by race and ethnicity, United States 2019
“The race and ethnicity- and age-standardized rate of late-stage AMD for women (0.94%; 95% UI, 0.57-1.43) was nearly identical to that for men (0.95%; 95% UI, 0.56-1.43).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The gender- and age-standardized rate of late AMD for non-Hispanic White individuals 40 years and older was 1.03% (95% UI, 0.65-1.52).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Late-stage AMD prevalence by state, United States 2019
“Age-, gender-, and race and ethnicity- standardized prevalence for those 40 years or older ranged from a low of 0.61% (95% UI, 0.40-0.88) in Hawaii to a high of 1.16% (95% UI, 0.76-1.69) in North Dakota” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We also estimated substantial variation in the prevalence of both early- and late-stage AMD at the state and county level, even after accounting for differences in demographics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global prevalence of the neovascular and geographic atrophy subtypes, by ethnicity
“Eight (21%) of the 39 studies provided information on geographic atrophy and neovascular subtypes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subgroup analysis showed similar overall prevalence of geographic atrophy (0·44%, 95% CrI 0·15–1·36) and neovascular age-related macular degeneration (0·46%, 0·18–1·08).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Europeans had a higher prevalence of geographic atrophy (1·11%, 95% CrI 0·53–2·08) than Africans (0·14%, 0·04–0·45), Asians (0·21%, 0·04–0·87), and Hispanics (0·16%, 0·05–0·46).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Neovascular AMD as a share of prevalent late-stage AMD
Natural history, survival, and mortality
Summary: natural history and mortality
In a meta-analysis of 53 studies including 4,362 participants with untreated neovascular AMD, mean visual acuity loss was 1 line at 3 months, 2.7 lines at 12 months, and 4 lines at 24 months; severe vision loss (more than 6 lines) occurred in 21.3% at 6 months and 41.9% by 3 years, and the proportion with visual acuity worse than 20/200 rose from 19.7% at baseline to 75.7% by 3 years. In the sham arm of the MARINA trial, 62.2% of participants lost fewer than 15 letters at 12 months and mean visual acuity decreased by 10.4 letters. The AAO attributes nearly 90% of AMD-related severe visual acuity loss (20/200 or worse) to the neovascular form. The AAO cites Salisbury Eye Study data linking visual acuity loss to activities of daily living and mortality risk, and a US cost-utility model estimated that 11 years of anti-VEGF therapy averts a 1.0 year-of-life loss.
Untreated neovascular AMD: systematic review and meta-analysis
“Four thousand three hundred sixty-two untreated neovascular AMD patients from published interventional studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean baseline VA among study patients was 0.64 logarithm of the minimum angle of resolution (logMAR) (approximately 20/87 Snellen). The mean VA change in logMAR progressed from 0.1 (1 line lost) at 3 months to 0.3 (2.7 lines lost) after 12 months and 0.4 (4 lines lost) after 24 months. The proportion of patients who developed severe vision loss (>6 lines) from baseline increased from 21.3% at 6 months to 41.9% by 3 years. The proportion of patients with VA worse than logMAR 1.0 (20/200 Snellen) increased from 19.7% at baseline to 75.7% by 3 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A doubling of the visual angle of presenting VA may be expected to occur in the year after initial presentation in eyes with untreated neovascular AMD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sham-injection arm of the MARINA trial
“At 12 months, 94.5% of the group given 0.3 mg of ranibizumab and 94.6% of those given 0.5 mg lost fewer than 15 letters, as compared with 62.2% of patients receiving sham injections (P<0.001 for both comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean increases in visual acuity were 6.5 letters in the 0.3-mg group and 7.2 letters in the 0.5-mg group, as compared with a decrease of 10.4 letters in the sham-injection group (P<0.001 for both comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Contribution of neovascular AMD to severe vision loss
Visual acuity loss, activities of daily living, and mortality
Long-term course after anti-VEGF treatment: atrophy and fibrosis
“Long-term follow-up studies have identified that the gains made in the first 2 years are not maintained in the long term238. In many instances, this loss can be attributed to under-treatment for a variety of reasons, including inability to access ongoing regular treatment, inappropriate treatment protocols and the burden of treatment for the clinician and patient. Besides patients dropping out of treatment, evidence shows that atrophy and fibrosis are important causes of vision loss despite good early results13.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Untreated neovascular AMD: proportion in each visual acuity loss stratum over time
“The percentage of patients with severe loss of vision (at least 6 lines of VA loss from the baseline visit) increased from 19.8% (14 studies with 1235 patients) at 6 months to 43.3% (9 studies with 743 patients) by 3 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Likewise, the proportion losing fewer than 3 lines decreased from 65.0% to 43.6% over the same period (Table 5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of patients losing between 3 and 6 lines at 3 months was 14.1%. This percentage peaked at 27.0% by 1 year and decreased to 18.2% at the 3-year time point.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Untreated neovascular AMD: progression to visual acuity worse than 20/200
“In 19.7%, VA was worse than 20/200 (legal blindness) at study inception, and this proportion increased to 50.3% by 3 months and to 77.6% by 3 years” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For example, at the 3-month time point the lower range of the confidence interval (CI) around the proportion of patients with vision worse than 20/200 was 26.2%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of patients whose VA worsened (defined generally as any deterioration from baseline) increased from 45.0% at 3 months to 81.1% by 2 years (Fig 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Macular neovascularization subtypes: consensus nomenclature
“Type 3 neovascularization is to be used when the vascular complex originates in the retina. Type 1 neovascularization is applied when the vessels originate from the choroid and remain under the RPE. Type 2 neovascularization is denoted if neovascularization that originates in the choroid breaks through the RPE to reach the subretinal space.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Macular neovascularization subtypes and their consequences: guideline
VEGF as a mediator of angiogenesis and vascular permeability
Proposed signaling pathway from lipoprotein debris to VEGF-driven MNV
“7-Ketocholesterol is thought to activate microglia to release cytokines, such as TNF, which mediates VEGF expression in RPE cells and its release preferentially from the basal aspects147. It has been further proposed that the secreted VEGF promotes choroidal endothelial cell activation and migration, potentially by interactions with integrins in ECM components148 and by activating GTPases, namely Rac1 (REF.145).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, the generated ROS presumably also diminish the RPE barrier integrity and permit secreted VEGF entry into the retina, which promotes choroidal endothelial cell migration, proliferation and eventually MNV formation149.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The conversion of non-exudative MNV to exudative MNV is likely to be a major disease transition point in neovascular AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Summary: diagnosis
The AAO Preferred Practice Pattern describes diagnosis based on history (metamorphopsia, decreased vision, scotoma), examination including stereoscopic biomicroscopy of the macula, and imaging. Optical coherence tomography (OCT) is described as important for detecting subretinal and intraretinal fluid and for monitoring response to therapy; fluorescein angiography is indicated to detect and characterize macular neovascularization, and OCT angiography had a pooled sensitivity of 0.87 and specificity of 0.97 for detecting macular neovascularization in a meta-analysis cited by the guideline.
Initial evaluation: history and examination
Optical coherence tomography
Optical coherence tomography angiography
Fluorescein angiography: indications and risks
Multimodal imaging: role of fluorescein angiography and OCT
“Although ophthalmoscopy might be sufficient for a basic diagnosis of AMD, fluorescein angiography is the gold standard for detecting and differentiating MNV. Furthermore, OCT imaging is particularly suitable for monitoring the disease, especially in the context of anti-VEGF therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On OCT, exudative activity typically presents with intraretinal and/or subretinal fluid.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient-facing description of diagnostic testing
Clinical presentation - signs and symptoms
Visual symptoms: metamorphopsia, central blur, and scotomas
Visual symptoms: guideline symptom history
“Metamorphopsia” (opens the source at this quote in a new tab)
“Decreased vision” (opens the source at this quote in a new tab)
“Scotoma” (opens the source at this quote in a new tab)
“Photopsia” (opens the source at this quote in a new tab)
“Difficulties in dark adaptation” (opens the source at this quote in a new tab)
Psychiatric symptoms: depressive symptoms at presentation for anti-VEGF therapy
“In a clinic-based cohort of 547 patients with nAMD who presented for treatment” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of depressive symptoms was 42.04% and 31.78% as per the CES-D-10 and MHI scales, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychiatric symptoms: depression and Charles Bonnet syndrome in guideline counseling
Visual hallucinations: Charles Bonnet syndrome prevalence meta-analysis
“We identified 18 studies with data on >4303 patients with AMD. We found an overall prevalence of CBS of 15.8% (95% confidence interval: 11.0%-21.2%). When looking at consecutively recruited patients with neovascular AMD from the clinic, prevalence of CBS was 7.2% (95% confidence interval: 4.3%-10.6%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual hallucinations: Charles Bonnet syndrome in a Danish neovascular AMD cohort
Psychiatric symptoms: mental health scores by visual acuity
“When stratified by VA, patients with a habitual VA of 20/200 or worse scored the lowest on mental health subscales scores: median of 43.8 (IQR: 31–62). Patients with a VA of 20/20 scored the highest: 87.5 (IQR: 81–94).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Functional symptoms: reading, face recognition, and driving
Functional symptoms: impaired activities of daily living at presentation
“The prevalence of impaired basic, instrumental and total ADL was 37.76%, 67.82% and 39.59%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Depressive symptoms [OR 2.08, 95% CI (1.08–4.00)], the presence of any disability [OR 3.16, 95% CI (1.64–0.07)] and never driving [OR 4.00, 95% CI (1.60–10.00)] were also positively associated with total ADL impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Functional symptoms: falls
Long-term morbidity
Summary: long-term morbidity
In the CATT trial, 480 of 1,059 eyes (45.3%) receiving anti-VEGF therapy developed scar by 2 years (fibrotic scar 24.7%, nonfibrotic scar 20.6%). A 2026 review reports that 20% to 67% of treated participants develop macular fibrosis within 2 to 7 years. In a US TriNetX cohort of 92,849 people with neovascular AMD, 21.24% had a diagnosis of visual impairment, the highest proportion among the single ocular diseases analyzed. Globally, 1.85 million people were blind and 6.23 million had moderate or severe vision impairment due to AMD in 2020. In a French nationwide cohort of 1,662 people with incident treated neovascular AMD, the condition was associated with a 19% increase in the risk of disability in activities of daily living and of mood disorders.
Scar formation during anti-VEGF therapy: CATT
“Scar developed in 480 of 1059 eyes (45.3%) by 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fibrotic scars developed in 24.7% of eyes, and nonfibrotic scars developed in 20.6% of eyes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Macular fibrosis as an end-stage complication
“Macular subretinal fibrosis represents the end-stage complication of neovascular age-related macular degeneration (nAMD). Despite the widespread use of anti-VEGF therapy, between 20 and 67% of nAMD patients develop this sight-threatening condition within 2 to 7 years, making fibrosis one of the main reasons responsible for anti-VEGF resistance and irreversible visual loss.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual impairment among people with neovascular AMD in the United States
“The prevalence of having a visual impairment which is composed of the sum of patients with low vision and blindness was highest among neovascular AMD patients at 21.24% and lowest among DR patients at 12.63% (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AMD as a cause of blindness in the United States
“The leading cause of blindness among white persons was age-related macular degeneration (54.4% of the cases), while among black persons, cataract and glaucoma accounted for more than 60% of blindness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global blindness and moderate or severe vision impairment due to AMD, 2020
“In 2020, 1.85 million (95%UI: 1.35 to 2.43 million) people were estimated to be blind due to AMD, and another 6.23 million (95%UI: 5.04 to 7.58) with MSVI globally. High-income countries had the highest number of individuals with AMD-related blindness (0.60 million people; 0.46 to 0.77).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disability and mood disorders after treated neovascular AMD: French nationwide cohort
“During the study period, 1662 cases of incident nAMD were identified. After adjustment for age, sex, Charlson comorbidity index and number of drugs, nAMD was significantly associated with the occurrence of ADL disability (Hazard ratio (HR): 1.19, 95% confidence interval (CI): 1.08–1.30; p = 0.0002) and of mood disorders (HR: 1.19, 95%CI: 1.07–1.32; p = 0.002). Associations with falls, fractures and head trauma were not statistically significant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Irreversible vision loss after interrupted anti-VEGF therapy
“When treatments are interrupted, discontinued, or both, irreversible vision loss can occur.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Outside of clinical trials, in clinical practice, patients with neovascular AMD who became LTFU during anti-VEGF therapy experienced significant visual decline at the return visit that persisted despite the normalization of retinal anatomic features with the resumption of care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Interruptions to anti-VEGF treatment led to irreversible vision loss that could not be recovered with the resumption of care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Wet age-related macular degeneration
Humanistic burden and health-related quality of life
Summary: humanistic burden
Time trade-off utility values in participants with AMD decline with visual acuity in the better-seeing eye, from 0.89 at 20/20 to 20/25 to 0.40 at counting fingers to light perception (80 participants); participants in the lowest visual acuity group were willing to trade 60% of remaining lifetime for perfect vision. National Eye Institute Visual Function Questionnaire-25 mental health subscale scores were lowest in participants with visual acuity of 20/200 or worse (median 43.8). Among 130 participants in a Norwegian survey, 33.1% reported stress in the week before an injection and 54.6% described the injection as uncomfortable.
Utility values by visual acuity in the better-seeing eye
| Visual acuity in the better-seeing eye | Time trade-off utility (95% CI) |
|---|---|
| Group 1: 20/20 to 20/25 | “0.89 (95% CI, 0.82-0.96)”View highlighted excerpt for this quote |
| Group 2: 20/30 to 20/50 | “0.81 (95% CI, 0.73-0.89)”View highlighted excerpt for this quote |
| Group 3: 20/60 to 20/100 | “0.57 (95% CI, 0.47-0.67)”View highlighted excerpt for this quote |
| Group 4: 20/200 to 20/400 | “0.52 (95% CI, 0.38-0.66)”View highlighted excerpt for this quote |
| Group 5: counting fingers to light perception | “0.40 (95% CI, 0.29-0.50)”View highlighted excerpt for this quote |
Time trade-off: lifetime traded for perfect vision
“Thus, those patients in group 1 were willing to trade 11% of their remaining lifetime in return for perfect vision in each eye, whereas those in group 5 were willing to trade 60% of their remaining lifetime in return for perfect vision in each eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Age-related macular degeneration causes a substantial decrease in patient utility values and is highly dependent on the degree of visual loss in the better-seeing eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Vision-related quality of life and mental health by visual acuity
“Eight hundred seventy-five patients were included in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When stratified by VA, patients with a habitual VA of 20/200 or worse scored the lowest on mental health subscales scores: median of 43.8 (IQR: 31–62). Patients with a VA of 20/20 scored the highest: 87.5 (IQR: 81–94).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline statement on quality of life
Emotional burden of intravitreal injections
“In total, 130 patients responded to the survey. The majority of patients reported to receive nine or more injections per year (48.8%), and many patients needed caregiver support for every treatment appointment (37.7%). Patients reported to be anxious one day (25.4%), two days (8.5%), one week (10.8%) or more than one week (3.1%) prior to treatment. The week before the treatment, 33.1% of patients reported to be stressed and 15.4% struggled to sleep. The majority of patients reported the treatment as uncomfortable (54.6%) or as somewhat painful (26.2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Barriers to treatment reported by patients and caregivers
Utility values by visual acuity used in a US cost-utility model
“Mean vision measurements in the VEGF-I cohorts and control cohorts each year were converted to utility format, ranging from a utility of 0.80 for 20/40 vision in the better-seeing eye to 0.538 associated with 20/630 vision, to calculate the yearly QALY accrual associated with therapy versus none” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The time tradeoff utilities were obtained from a visual utility database of 1,400 ophthalmic patient interviews.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinic time and post-injection recovery time reported by patients
Economic burden and healthcare resource utilization
Summary: economic burden and resource utilization
In 2024, Medicare Part B spending was $2.37 billion for aflibercept 2 mg (Eylea), $1.92 billion for faricimab (Vabysmo), $0.67 billion for aflibercept 8 mg (Eylea HD), and $0.13 billion for ranibizumab (Lucentis); these totals include all approved indications (for example, diabetic macular edema and retinal vein occlusion), not neovascular AMD alone. In 2020, aflibercept was the second-highest Medicare Part B drug by total spending (more than $3 billion). In a US commercial claims cohort of 6,076 participants with neovascular AMD, annual neovascular AMD-related outpatient visit costs were $8,658 for active choroidal neovascularization compared with $2,406 for inactive disease. In a US survey of 200 participants, mean annual societal ophthalmic costs were $39,910 with visual loss and $6,116 with good vision, rising to $82,984 at 20/800 or worse. Each treatment visit required a mean of 90 minutes in clinic, and patients reported almost 12 hours per visit including travel and recovery. In the IRIS Registry, 11.6% of 156,327 treatment-naive participants were lost to follow-up within 12 months.
Medicare Part B spending on intravitreal anti-VEGF products, 2024 (all indications)
| HCPCS code and product | Total spending, 2024 ($) | Claims, 2024 | Beneficiaries, 2024 |
|---|---|---|---|
| J0178 aflibercept 1 mg (Eylea) | “2365369089” | “1233027” | “293280” |
| J2777 faricimab-svoa 0.1 mg (Vabysmo) | “1918151107” | “792936” | “172503” |
| J0177 aflibercept hd 1 mg (Eylea Hd) | “665780687.8” | “211930” | “66767” |
| J2778 ranibizumab 0.1 mg (Lucentis) | “128919304.6” | “144995” | “33741” |
| J9035 bevacizumab 10 mg (Avastin) | “161538584.4” | “342609” | “98961” |
Medicare Part B spending on AMD therapies, 2020
“Aflibercept was the second most expensive drug by total spending for the Medicare Part B program in 2020, with more than $3 billion in annual costs, while ranibizumab was the sixth most expensive drug by total spending, costing more than $1 billion; spending on aflibercept and ranibizumab together was more than 10% of the total Medicare Part B drug spending for 2020.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These cost differences have implications for both the Medicare program and beneficiaries, as these patients are liable for 20% of the treatment cost.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare Part B spending per beneficiary, 2011 to 2015
“On average, Medicare spent $9719 and $9934 annually on each beneficiary receiving ranibizumab and aflibercept injections, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ranibizumab and aflibercept costs account for 12% of the Medicare Part B budget annually.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare average sales prices for anti-VEGF agents
Direct costs and resource use by disease activity: US commercial claims
“A total of 6,076 patients with nAMD were identified for the prevalent cohort; 60.1%, 17.2%, and 5.9% had active CNV, inactive CNV, and inactive scar disease stage at index, respectively. The nAMD-related outpatient visit costs were roughly 4 and roughly 7 times higher, respectively, for the active CNV group ($8,658 [SD = $11,612]) compared with the inactive CNV ($2,406 [SD = $5,510]) and inactive scar ($1,198 [SD = $3,035]) groups (P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 3,623 prevalent patients (59.6%) were eligible for the anti-VEGF treatment patterns analysis (mean [SD] duration of therapy = 7.7 [4.5] months; mean [SD] number of injections = 6.0 [3.7]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Societal costs by visual acuity in the better-seeing eye
“The mean annual societal cost for the Control Cohort was $6,116 and for the Study Cohort averaged $39,910 (P < 0.001). Study Subcohort 1 costs averaged $20,339, while Subcohort 4 costs averaged $82,984.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Total societal ophthalmic costs associated with neovascular age-related macular degeneration dramatically increase as vision in the better-seeing eye decreases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment burden: time-and-motion study
“Fifty-six physicians provided data for 221 patients with neovascular AMD. Patients accounted for 20% of the health care staff's time per week, with an average of 23 staff members. An average patient visit for neovascular AMD was 90 minutes (range: 13 minutes to >4 hours). Patients reported an average time per visit of almost 12 hours, including preappointment preparation (16 minutes), travel (66 minutes), waiting time (37 minutes), treatment time (43 minutes), and postappointment recovery (9 hours).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Loss to follow-up during anti-VEGF therapy: IRIS Registry
“For neovascular AMD, 11.6% of patients (95% CI, 11.4%-11.7%) were LTFU, and 88.4% of patients were followed up within 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nearly 1 of 9 patients with neovascular AMD treated with anti-VEGF injections became LTFU, whereas 1 of 7 patients were nonpersistent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Annual per-patient costs in commercially insured neovascular AMD, 2018 US dollars
“All costs were adjusted to 2018 US dollars using the medical care component of the Consumer Price Index.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We estimated an annual all-cause cost for patients with nAMD of $24,520 per patient, whereas newly diagnosed patients incurred slightly lower costs ($18,943).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The nAMD-related outpatient costs represented 28% of total costs and 44% of total outpatient costs, respectively, and were driven primarily by anti-VEGF injection-related costs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual healthcare resource utilization by baseline disease status: US commercial claims
Determinants of neovascular AMD-related outpatient costs
“Significant drivers of total nAMD-related costs were the initial anti-VEGF agent and anti-VEGF injection frequency” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Multivariate GLM results revealed an increasing trend in costs with increasing anti-VEGF injection frequency; there were 73% higher costs for patients with 4-6 injections to 342% higher costs for those with 10 or more injections compared with those with 1-3 injections over 1 year of follow-up” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anti-VEGF injection frequency and treatment disruption by initial agent
“Mean duration of therapy (SD) and mean (SD) number of injections was lowest for the bevacizumab group (n = 1,876 [51.8%]; 6.0 [4.6] months and 4.8 [3.3] injections, respectively) compared with the ranibizumab (n = 539 [14.9%]; 7.6 [4.4] months and 6.0 [3.6] injections, respectively) and aflibercept groups (n = 1,208 [33.3%]; 7.9 [4.4] months and 6.1 [3.9] injections, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nearly half (48.3%) of all patients (n = 1,750) had a treatment disruption.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Staff members and staff time dedicated to neovascular AMD management per retina practice
Retina specialist reported burden of monitoring and injection frequency
“When asked about the impact of activities for monitoring and injection administration on staff time, the majority of the surveyed retina specialists (62%, 35 of 57) felt that frequency of patient monitoring placed a significant burden on staff time. A large percentage of retina specialists (58%, 33 of 57) felt that billing and filing for reimbursement was also a significant burden on staff resources.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-nine percent (28 of 57) of retina specialists reported that the frequency of injections was an impactful burden on office space, including waiting rooms and examination rooms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Two-thirds of physicians (38 of 57) stated they would find it very desirable to reduce office visits.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Wet age-related macular degeneration on families
Summary: economic impact on families
Caregivers of people receiving anti-VEGF therapy carry a documented time and cost burden. In a UK survey of 250 patient-caregiver pairs, 70.8% of caregivers had attended 10 or more appointments in the previous year, 24.8% required time off work, and caregivers reported loss of income as a consequence. In a US time-and-motion study, caregivers took time away from work (22%) and personal activities (28%) to provide transportation. In a nine-country survey, 56.7% of 910 participants were usually taken to appointments by a caregiver, and a caregiver being unable to take the patient was the most common reason for a missed appointment (25.9%). In a US societal cost survey, direct nonmedical costs, primarily caregiver costs, made up 67.1% of societal ophthalmic costs in participants with visual loss.
Caregiver costs as a share of societal costs
“Direct nonmedical costs, primarily caregiver, comprised 67.1% of Study Cohort societal ophthalmic costs, versus 21.3% ($1,302/$6,116) of Control Cohort costs (P < 0.001) and 74.1% of 20/800 to no light perception subcohort costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver time away from work for transportation to appointments
Caregiver burden during ranibizumab therapy: UK survey
“This is a cross-sectional questionnaire survey of 250 matched patient caregiver dyads across three large ophthalmic treatment centres in United Kingdom.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common eye-related care activity undertaken was accompanying patients for their eye clinic appointments, with 70.8% carers having attended ≥10 appointments over the last year. On an average, the caregivers reported that 70% spent at least half a day and 43.6% spent most of the day assisting their patient with their clinic visit every 4–6 weeks. 24.8% of caregivers required time off work to support patients with their eye treatment, and 10% of them reported that this led to a loss of income.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ranibizumab therapy for nAMD is associated with significant caregiver burden. Both disease impact and treatment frequency contributed to the overall burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Escorts to injection visits and missed appointments: nine-country survey
“The majority of patients (82.1%; n=747/910) received support from a caregiver.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most caregivers always attended appointments (60.1%; n=535/890)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the 15.7% (n=143/910) of patients who missed a clinic appointment, the main obstacles were that the caregiver was unable to take them to the appointment (25.9%; n=37/143), fear about receiving an injection (21.0%; n=30/143), and patient illness (reason not stated) (18.9%; n=27/143).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients (56.7%; n=516/910) were usually taken to the appointment by a caregiver; however, 20.4% (n=186/910) went by public transport, 12.4% (n=113/910) drove themselves, 8.1% (n=74/910) used a taxi, and 2.3% (n=21/910) were taken by an ambulance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other barriers included treatment costs (27.8%; n=253/910)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver distress and respite
“Most caregivers were family caregivers and were found to be compassionate and self-sacrificing. They accepted additional responsibility whilst providing an encouraging environment for their care recipient. As a result, they experience distress and consider their own needs as secondary. Very few seek or receive respite and this added burden can have a negative impact upon the relationship between caregiver and care recipient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Who transports patients to injection visits: US time-and-motion survey
“The majority of patients (72%, 54 of 75) were driven to their appointment by a caregiver. Their caregiver was a spouse or partner (65%, 35 of 54), an adult child or grandchild (22%, 12 of 54), a friend (7%, 4 of 54), or another person (6%, 3 of 54).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty percent (15 of 75) of patients drove themselves, while 8% (6 of 75) took a car service or public or government transportation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket transportation costs and household income of participants
“Few patients experienced direct out-of-pocket transportation costs. Eighty-nine percent (67 of 75) reported that they did not pay any transportation costs for their latest clinic visit. Among those who had out-of-pocket transportation cost, 12% (8 of 67) paid for parking, 6% (4 of 67) paid tolls, and 3% (2 of 67) paid bus fare.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average income was $40 000. The majority of patients (62%, 46 of 75) reported an income of less than or equal to $50 000.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Composition of caregiver costs and employment effects of severe vision loss
“Direct nonmedical, or caregiver, costs included 27% for paid caregivers and 73% for unpaid caregivers,” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Inside activities of daily living costs comprised 50% of caregiver costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Those with severe difficulty seeing (<20/200), however, earned a median $2,564 per month (98% that of a nondisabled person) but were only 47% as likely to be employed as people without disabilities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Summary: economic impact of diagnostic testing
Diagnosis and retreatment decisions rely on retinal imaging, principally OCT (CPT 92134), with fluorescein angiography when indicated. In a US Medicare analysis covering 2008 to 2015, reimbursement for OCT imaging used to guide anti-VEGF therapy for neovascular AMD totaled an estimated $0.8 billion, while OCT-guided personalized dosing was estimated to have saved Medicare $10.3 billion in anti-VEGF drug and injection costs, for a net government saving of $9.0 billion. The estimated annual beneficiary copayment for OCT imaging was $6, compared with $242 for aflibercept on a personalized injection schedule. No current Medicare fee schedule amount for OCT or fluorescein angiography was retrieved from a primary CMS source.
Medicare spending on OCT imaging and savings from OCT-guided therapy
“Using the meta-analysis and survey data, we calculated the cost of using OCT imaging to guide anti-VEGF treatment decisions from 2008– 2015 was $0.8 billion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to the fixed-regimen spending totals, OCT-guided personalized-treatment regimens enabled Medicare to save $10.3 billion dollars on anti-VEGF therapy costs for nvAMD from 2008 – 2015.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From 2008 – 2015, the United States government and nvAMD patients have accrued an estimated savings of $9.0 billion and $2.2 billion, respectively, from the use of OCT to guide personalized anti-VEGF treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Beneficiary copayment for OCT imaging
| Cost component | Ranibizumab | Bevacizumab | Aflibercept |
|---|---|---|---|
| Drug copay cost, personalized-injection schedule | “$288”View highlighted excerpt for this quote | “$9”View highlighted excerpt for this quote | “$242”View highlighted excerpt for this quote |
| OCT imaging copay cost, personalized-injection schedule | “$6”View highlighted excerpt for this quote | “$6”View highlighted excerpt for this quote | “$6”View highlighted excerpt for this quote |
| Injection copay cost, personalized-injection schedule | “$20”View highlighted excerpt for this quote | “$20”View highlighted excerpt for this quote | “$20”View highlighted excerpt for this quote |
Imaging billing codes used in Medicare claims analysis
“Main outcome measures were spending by Medicare as tracked by Current Procedural Terminology codes on intravitreal injections (67028), retinal OCT imaging (92134) and anti-VEGF treatment-specific J-codes (J0178, J2778, J9035, J3490 and J3590).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Optical coherence tomography visits over 12 months by baseline disease status
| Optical coherence tomography test-related visits over 12 months | All prevalent nAMD (N = 6,076) | Active CNV (N = 3,653) | Inactive CNV (N = 1,046) | Inactive scar (N = 358) |
|---|---|---|---|---|
| Patients with at least 1 visit, n (%) | “5,350 (88.1)”View highlighted excerpt for this quote | “3,384 (92.6)”View highlighted excerpt for this quote | “893 (85.4)”View highlighted excerpt for this quote | “253 (70.7)”View highlighted excerpt for this quote |
| Number of unique visits, mean (SD) | “4.5 (3.5)”View highlighted excerpt for this quote | “5.4 (3.6)”View highlighted excerpt for this quote | “2.9 (2.6)”View highlighted excerpt for this quote | “1.6 (1.9)”View highlighted excerpt for this quote |
Approaches to treatment
Current treatment options and standard of care
Anti-VEGF intravitreal injections
Anti-VEGF therapy as first-line treatment for neovascular AMD
NICE recommendation for anti-VEGF treatment of late AMD (wet active)
Aflibercept 2 mg and 8 mg
Ranibizumab 0.5 mg
Bevacizumab (off-label intravitreal use)
Brolucizumab
Ranibizumab and aflibercept biosimilars
Aflibercept 8 mg: participants maintaining 12-week and 16-week intervals through week 48 in PULSAR
“A total of 251 (79%) of 316 patients in the aflibercept 8q12 group and 239 (77%) of 312 patients in the aflibercept 8q16 group maintained their assigned dosing regimen up to week 48. Overall, 523 (83%) of 628 patients who received aflibercept 8 mg maintained at least 12-week dosing intervals up to week 48.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Least squares mean change from baseline in BCVA letter score at week 48 was +6·1 (95% CI 4·6–7·6) letters in the aflibercept 8q12 group, +5·9 (4·5–7·3) letters in the 8q16 group, and +7·0 (5·6–8·5) letters in the aflibercept 2q8 group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aflibercept 8 mg and 2 mg: serious ocular events, intraocular inflammation, and thromboembolic events in PULSAR
“Serious ocular TEAEs in the study eye occurred in 13 (1·3%) of 1009 patients” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“no cases of endophthalmitis or retinal vasculitis were reported. All cases of intraocular inflammation were mild or moderate in severity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eight cases of arteriothrombotic events, assessed and categorised by an Anti-Platelet Trialists’ Collaboration adjudication committee, were reported, with no clinically relevant differences observed across groups” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aflibercept: intraocular inflammation and vision loss with denominators in HAWK and HARRIER, and postmarketing occlusive event rate
“The SRC reviewed data from cases of investigator-reported IOI (60/1088 brolucizumab-treated eyes; 8/729 aflibercept-treated eyes).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Incidence of IOI in aflibercept-treated eyes was 1.1%, with at least moderate visual acuity loss in 0.14%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The overall rates of moderate or severe visual acuity loss, including visual acuity loss associated with definite/probable IOI, retinal vasculitis, and/or retinal occlusion, were 7.4% (81/1088) and 7.7% (56/729) in brolucizumab- and aflibercept-treated eyes, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A recent review of data from the postmarketing aflibercept Global Safety Database indicated that retinal arterial occlusion, vasculitis, or severe vision loss occurred at a rate of 0.9 per 10 000 aflibercept injections.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bispecific Anti-VEGF and angiopoietin-2 antibodies
Faricimab: mechanism and approval
Faricimab: TENAYA and LUCERNE dosing intervals and injection counts
Faricimab: intraocular inflammation and retinal vasculitis reports
Faricimab: dosing interval distribution at week 48 in TENAYA and LUCERNE with participant counts
“At week 48, approximately 80% of faricimab-treated patients in both TENAYA and LUCERNE were on 12-week or 16-week dosing intervals, with 107 (34·0%) patients in TENAYA and 104 (32·9%) patients in LUCERNE on extended dosing regimens of every 12 weeks, and 144 (45·7%) patients in TENAYA and 142 (44·9%) patients in LUCERNE on 16-week dosing” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“More than 95% of patients in the faricimab group in both studies avoided losing 15 letters or more of vision from baseline at primary endpoint visits” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Faricimab and aflibercept: intraocular inflammation and endophthalmitis in TENAYA and LUCERNE
“In TENAYA and LUCERNE, at week 48, rates of intraocular inflammation were low and on average reported in 2·0% of patients receiving faricimab and 1·2% of patients receiving aflibercept” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Two intraocular inflammation events (one uveitis in TENAYA, one vitritis in LUCERNE) in the faricimab group and one uveitis event (LUCERNE) in the aflibercept group led to a decrease of 30 or more letters in visual acuity score lasting more than 1 h” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was one report of endophthalmitis in the aflibercept group of LUCERNE, which was culture negative.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Port delivery system with ranibizumab
Surgically implanted refillable ranibizumab reservoir
Endophthalmitis across Ladder, Archway, and Portal
“The United States Prescribing Information has a Boxed Warning for endophthalmitis” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twelve endophthalmitis events were reported in 11 patients (11/555 [2.0%]) through March 12, 2021.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Seven cases (7/11 [63.6%]) had preceding/concurrent conjunctival complications.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Archway: ocular adverse events of special interest with denominators through week 40
“Ocular adverse events of special interest were reported in 47 patients (19.0%) and 10 patients (6.0%) in the PDS Q24W and monthly ranibizumab arms, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“endophthalmitis occurred in 4 patients (1.6%) in the PDS Q24W arm; all events were serious and occurred outside of the postoperative period at days 57, 59, 161, and 282.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Iritis occurred in 50 patients (20.2%) in the PDS Q24W arm, with 48 patients experiencing events in the postoperative period, consistent with expected postoperative inflammation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the PDS Q24W arm, 18 patients (7.3%) required 22 additional surgical procedures related to ocular adverse events of special interest, including cataract extraction, conjunctival repair, and vitrectomy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Archway: supplemental ranibizumab before the first refill-exchange
“A total of 246 PDS-treated patients were assessed for supplemental ranibizumab treatment at week 16, week 24, or both, excluding 2 patients who discontinued study treatment before week 16.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 4 PDS-treated patients (1.6%) who were assessed for supplemental treatment received supplemental treatment before the first refill-exchange procedure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Port delivery system endophthalmitis: basis of the boxed warning, severity, and timing of onset
“This warning was issued due to the observation that PDS-treated patients experienced endophthalmitis at a 3-fold higher rate (1.7%) compared with patients receiving monthly intravitreal injections (0.5%) during the controlled phase of the PDS nAMD studies of Ladder and Archway.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“all patients experienced moderate (4/11 [36.4%]) or severe (7/11 [63.6%]) endophthalmitis when events were analyzed by greatest intensity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were 2 cases (2/555 [0.4%]) of postoperative endophthalmitis consistent with acute postoperative endophthalmitis. All other cases had a late onset and occurred >37 days after the PDS implant insertion procedure and were consistent with delayed onset endophthalmitis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Verteporfin photodynamic therapy
Current role of photodynamic therapy in the United States
NICE recommendations on photodynamic therapy
EURETINA recommendation on laser photocoagulation and photodynamic therapy
“While largely superseded by intravitreal pharmaceutical VEGF inhibition, these two older forms of CNV treatment remain a rational therapeutic option for selected patients in whom VEGF inhibition is not advisable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AREDS2 antioxidant vitamin and mineral supplementation
Fellow-eye risk reduction in unilateral neovascular AMD
Limitations of current therapies
Summary
Current treatment of neovascular AMD relies on repeated intravitreal injections of anti-VEGF agents given monthly, every 8 weeks, or at extended intervals of up to 16 weeks under treat-and-extend or personalized-interval regimens, with continuous office monitoring. Real-world patients receive fewer injections than trial participants and have smaller visual gains: in 49,485 treatment-naive United States eyes, the mean gain at 1 year was 0.95 letter after a mean of 7.3 injections; in the eight-country AURA study (2,227 patients), mean gains were +2.4 letters at year 1 and +0.6 letters at year 2 with 5.0 and 2.2 injections; and in LUMINOUS (3,379 treatment-naive patients with 1-year data), the mean gain was 3.1 letters with 5.0 injections. In one United States retina practice, 2,003 of 9,007 patients (22.2%) were lost to follow-up for 12 months or longer after an injection. In CATT, vision gains from the first 2 years were not maintained at 5 years. Agent-specific safety limitations include intraocular inflammation with retinal vasculitis or occlusion after brolucizumab (definite or probable intraocular inflammation in 4.6% of brolucizumab-treated eyes in HAWK and HARRIER) and endophthalmitis in 11 of 555 participants (2.0%) who received the port delivery system with ranibizumab, which carries a boxed warning and was voluntarily recalled in 2022 before reintroduction in 2024. Payer prior authorization requests for anti-VEGF agents were approved in 96.2% of cases but delayed care by more than 24 hours in 59.6% of approvals.
Real-world undertreatment and visual outcomes: United States retina database
“At 1 year, after a mean of 7.3 anti-VEGF injections, there was a mean gain of 1 letter (0.95 letter; 95% confidence interval [CI] for change in VA, +0.77 to +1.13 letter; P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Real-world nAMD patients receive fewer anti-VEGF injections and experience worse visual outcomes compared with patients receiving fixed, frequent therapy in randomized controlled trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Older patients and those with poor baseline VA may be particularly prone to undertreatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world visual outcomes: AURA multi-country study
“Mean change in visual acuity score from baseline to years 1 and 2 was +2.4 and +0.6 letters, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients received a mean of 5.0 and 2.2 injections in the first and second year, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In clinical practice, fewer injections are administered than in clinical trials. Anti-VEGF treatment resulted in an initial improvement in visual acuity; however, this was not maintained over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world visual outcomes: LUMINOUS treatment-naive patients
Nonadherence and loss to follow-up
Long-term vision loss despite anti-VEGF treatment
Injection frequency and treatment burden: sponsor description
Brolucizumab: intraocular inflammation, retinal vasculitis, and occlusion
“On the basis of these cases, incidence of definite/probable IOI was 4.6% (IOI + vasculitis, 3.3%; IOI + vasculitis + occlusion, 2.1%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were 8 cases (incidence 0.74%) of at least moderate visual acuity loss (≥15 ETDRS letters) in eyes with IOI (7 in eyes with IOI + vasculitis + occlusion).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Port delivery system with ranibizumab: endophthalmitis and device complications
Prior authorization delays for anti-VEGF agents
“Of the 2140 approvals, 59.6% (1277) resulted in a delay in care greater than 24 hours, and 40% (863) were given on the date of service.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median staff time spent to obtain a single PA was 100 (range, 0-200) minutes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring visits during extended-interval dosing in the faricimab phase 3 trials
“Finally, the assessment of the potential for faricimab to reduce treatment burden and improve quality of life might also be limited by the fact that at the time of the primary analysis, all patients returned for monthly visits to maintain masking.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Brolucizumab: postmarketing event rates per 10 000 injections and timing of inflammation onset
“On August 28, 2020, postmarketing data indicated that Novartis had received reports of evidence of associated retinal vasculitis and retinal vascular occlusion at a rate of 4.71 per 10 000 brolucizumab injections, while individual events of retinal vasculitis and retinal vascular occlusion were reported at rates of 3.61 and 2.35 per 10 000 injections, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately three quarters of cases of each event occurred within the initial 6 months after the first injection.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, patients whose first IOI-related event occurred more than 12 months after the first injection had no reported vision loss at the end of the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity change by anti-VEGF injection count over 1 year
“At the lower range, those patient eyes that received 4 anti-VEGF injections or fewer in the first year of treatment generally lost vision, approximately 2 to 3 letters at 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the mid range, a linear relationship was found between mean letters gained and mean number of anti-VEGF injections, up to 10 injections over 1 year, after which the relationship plateaued at approximately 3 to 4 letters gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patient eyes that received 4 anti-VEGF injections or fewer over 1 year generally showed worse mean baseline VA than those patient eyes that received a greater number of injections over 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Those who received 1 anti-VEGF injection had a mean baseline age of 81.1 years, whereas those who received 13 injections over 1 year had a mean baseline age of 78.4 years” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Variable-frequency regimens and the gap from registration-trial outcomes
“Registration trials for ranibizumab (monthly) and aflibercept (every 2 months after 3 monthly loading doses) and the monthly ranibizumab and bevacizumab arms of CATT show an average 1-year improvement of 8.5 letters across these studies” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 2015 American Society of Retina Specialists Preferences and Trends Survey of more than 2700 retina specialists in 60 countries revealed that more than 90% of retina specialists, both in the United States and internationally, use OCT-guided variable frequency anti-VEGF treatment protocols for nAMD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Multiple prospective RCTs have demonstrated that variable frequency anti-VEGF therapy for nAMD results in a less favorable visual outcome compared with fixed, frequent anti-VEGF suppression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Consequently, attempts to limit treatment burden through the adoption of variable frequency anti-VEGF treatment regimens must be approached cautiously.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Loss to follow-up and nonpersistence: national registry rates and risk factors
“This big data retrospective cohort study from the IRIS Registry of 185 138 eyes of 156 327 patients who were documented with treatment-naive neovascular AMD and subsequently were treated with anti-VEGF therapy in the United States disclosed an LTFU rate of 11.6%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Risk factors for being LTFU included increasing age, male sex, Black or African American race or ethnicity, diabetes, unilateral involvement, and Medicaid health insurance. The rate of nonpersistence in this same cohort was 14.3%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Health insurance is also a risk factor because patients with Medicaid insurance were more likely to be LTFU and nonpersistent, whereas patients with Medicare insurance were less likely to be LTFU and nonpersistent than patients with private insurance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients who were LTFU, the average time from the first intravitreal injection to the last visit was 2.4 years and was 4.4 years for patients not LTFU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity at last visit by follow-up status
“Compared with patients without nonpersistence during the same follow-up period, a lower percentage of patients with nonpersistence showed VA of 20/40 or better (35% vs. 43%; P < 0.001) at the last visit” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with patients without nonpersistence during the same follow-up period, a higher percentage of patients with nonpersistence lost > 5 ETDRS letters (40% vs. 36%; P < 0.001; Table 5) in the treated eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twelve percent of patients who were LTFU did later undergo follow-up (defined as after the first year and within 4 years of the last anti-VEGF intravitreal injection).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary
Vorolanib intravitreal insert is investigational and has not been approved by the FDA. LUGANO (in the full dataset) and LUCIA did not meet their primary best-corrected visual acuity noninferiority endpoints, and on October 19, 2026, EyePoint announced that it would conclude both phase 3 wet AMD trials early and prioritize development in diabetic macular edema; no approved population or label for wet AMD is defined. EyePoint had anticipated a New Drug Application in the first half of 2027, contingent on LUCIA results; on November 12, 2026, it stated that it will conclude the wet AMD program before completion of the full second year of both trials and will complete additional analyses to assess next steps in wet AMD, and it has announced no New Drug Application for wet AMD. In the phase 3 trials, the insert (2.7 mg, delivered as 2 inserts in a single injection) was given every 6 months starting at month 2, after aflibercept loading doses, with supplemental aflibercept allowed by prespecified disease-activity criteria. The trials enrolled both treatment-naive participants (75.4% of the LUGANO insert arm) and previously treated participants, who needed at least 2 anti-VEGF injections in the prior 6 months. The phase 2 DAVIO 2 trial enrolled only previously treated participants. In these designs, the use studied was maintenance therapy after anti-VEGF induction, with rescue anti-VEGF injections as needed, in treatment-naive or previously treated patients. The sponsor expects physicians to incorporate the product into existing treatment approaches. Administration is an office-based intravitreal injection, the same care setting as current anti-VEGF therapy. An independent 2025 review stated that larger controlled trials are needed to define the clinical role of sustained-release tyrosine kinase inhibitors.
Investigational status, NDA plan contingent on LUCIA, and early conclusion of the wet AMD trials
Phase 3 population: treatment-naive and previously treated patients
Dosing after anti-VEGF loading: LUGANO presentation
Sponsor-proposed role alongside current therapies
Care setting: office-based intravitreal injection
Independent review of sustained-release tyrosine kinase inhibitors
“Sustained delivery of VEGF receptor TKIs represents a promising therapeutic paradigm for retinal and choroidal vascular diseases, potentially reducing treatment burden while maintaining efficacy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Continued evaluation through larger, controlled clinical trials is essential to validate these early findings and define the role of these agents in clinical practice.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Independent review: rationale for local rather than systemic delivery of tyrosine kinase inhibitors
“These systemic profiles inform the safety considerations of repurposing these agents for intraocular or systemic delivery in retinal and choroidal vascular diseases, where minimizing systemic exposure is paramount.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events such as gastrointestinal symptoms and elevated liver enzymes mirror those commonly reported with systemic TKI use in oncology.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This overlap underscores the importance of optimizing delivery routes to minimize systemic exposure while preserving ocular efficacy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Heterogeneity of treatment effect
Summary
Formal subgroup results from LUGANO have not been published; EyePoint stated that subgroup analyses would be presented at retina meetings beginning with the Retina Society meeting of September 23 to 26, 2026. In the topline data, 9 of 211 participants (4%) in the vorolanib insert arm lost 15 or more letters from causes the sponsor attributed to conditions other than wet AMD: geographic atrophy (6), glaucoma (2), and retinal detachment (1). No aflibercept participants lost vision from such causes. Baseline history of glaucoma in the study eye was 11.4% in the insert arm and 5.9% in the aflibercept arm. Geographic atrophy lesions were closer to the fovea at baseline in the insert arm (825 versus 1,009 microns). Excluding these 9 participants was an ad hoc analysis. The prespecified supplement-free subgroup (113 participants, 54%) met noninferiority (nominal p = 0.0035). The EyePoint chief executive officer stated that visual acuity results were similar in treatment-naive and treatment-experienced participants, but no numerical subgroup results have been released. In DAVIO 2, which enrolled only previously treated participants, EyePoint reported that visual and anatomic outcomes were not meaningfully influenced by baseline visual acuity, duration of wet AMD, or prior treatment burden. These subgroup findings are sponsor-reported, partly post hoc, and not peer reviewed.
LUGANO: participants with vision loss unrelated to wet AMD
LUGANO: causes of vision loss and baseline geographic atrophy location
LUGANO: supplement-free subgroup
LUGANO: treatment-naive versus previously treated participants
LUGANO: planned subgroup presentations
DAVIO 2: consistency across baseline characteristics in previously treated participants
Anti-VEGF comparator context: visual gains by baseline visual acuity
“Stratified by BLVA <23 (n = 382), 23 to <39 (n = 559), 39 to <60 (n = 929), 60 to <74 (n = 994), and ≥74 (n = 515), visual acuity change was 12.6 (20.63), 6.7 (17.88), 3.6 (16.41), 0.3 (13.83), and −3.0 (11.82) letters, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity loss by choroidal neovascularization lesion subtype: untreated eyes
“Based on these studies, at 12 months 33.2% (95% CI, 19.3%-48.7%) of patients with occult choroidal neovascularization had lost between 3 and 6 lines of VA, compared with 43.7% (95% CI, 28.0%- 60.1%) of patients with classic choroidal neovascularization. This difference was not significant, as reflected by the overlapping CIs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the 41 treatment arms reporting the location of choroidal neovascularization relative to the fovea, most patients had subfoveal disease (81.4%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We were unable to confirm or refute the commonly held clinical perception that the natural history of visual function is influenced by angiographic choroidal neovascularization subtype.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baseline visual acuity and injection intensity: real-world United States eyes
“Greater mean 1-year change in VA also trended with worse baseline VA; those patients with better VA at presentation tended to be particularly vulnerable to vision loss.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Specifically, patients with baseline VA of 20/200 or worse, 20/70 to 20/200, 20/40 to 20/70, and 20/40 or better received 6.5, 7.4, 7.5, and 7.3 anti-VEGF injections, respectively, over 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Specifically, those patients with baseline VA of 20/40 or better tended to lose VA at 1 year, regardless of anti-VEGF injection frequency. However, these patients also showed better final VA compared with those patients with worse baseline VA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean 1-year change in VA tended to increase in patients with both increased anti-VEGF injection frequency and decreased baseline VA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
Anti-VEGF dosing regimens: fixed, as-needed, treat-and-extend, and personalized intervals
NICE: agent selection by cost and switching
Payer coverage restrictions and step therapy prevalence
“Descriptive assessment showed that approximately 65% of commercial coverage decisions and approximately 52% of MA decisions included restrictions beyond the FDA label.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Coverage decisions for originator products were more likely to include restrictions compared with those for biosimilar products.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Step therapy protocols were found in up to 75% of plans but were variable by drug, with most requiring a first-line trial of bevacizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare Advantage step therapy and prescribing of bevacizumab
“The difference-in-differences regressions found a 7.8% (95% CI, 4.9%-10.7%; P < .001) greater probability of being prescribed bevacizumab for the first administration due to step therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Step therapy was not significantly associated with an increased rate of medication switching (hazard ratio, 0.86; 95% CI, 0.71-1.06; P = .15).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare Part B anti-VEGF use after step therapy
“After step therapy implementation, relative usage of aflibercept increased by 32.0%, while there was a decrease in relative usage of bevacizumab by 33.2% and ranibizumab by 4.3%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Step therapy has not significantly increased bevacizumab usage on an aggregate level.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bevacizumab-first step therapy outcomes at an academic center
“After 1 year, mean ΔVA was +8.4 letters (95% CI: +6.1 to +10.6 letters). 86% had treatment success, and 6% of eyes had switched to aflibercept.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“11% (n = 38) of eyes were switched to aflibercept.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prior authorization for anti-VEGF agents in retina practices
“Overall, 2140 (96.2%) requests were approved.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, PA denial for step therapy was 2.9% (65 of 2225) of requests and uncovered diagnoses was 0.9% (20 of 2225) of requests.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Step therapy policy review
PULSAR: criteria for shortening the dosing interval and the limit on extension in year 1
“Beginning at week 16, patients receiving aflibercept 8 mg were assessed and the dosing interval was shortened if the following DRM criteria were met: BCVA loss of more than 5 letters from week 12 and either a more than 25 μm increase in central retinal thickness (CRT) from week 12 or new foveal haemorrhage or neovascularisation” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients in the aflibercept 8q12 and 8q16 groups who met the DRM criteria at week 16 or week 20 had their interval shortened and subsequently received aflibercept 8 mg every 8 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The minimum interval for all patients was 8 weeks, and dosing intervals could not be extended within the first year of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
TENAYA and LUCERNE: disease activity assessment for interval assignment and the personalised treatment interval regimen
“After the first four monthly doses (day 1, and weeks 4, 8, and 12), patients in the faricimab group were assessed at weeks 20 and 24 for protocol-defined disease activity based on structural and functional criteria and treating physician clinical assessment” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients in the faricimab group who did not have active disease at weeks 20 and 24 received faricimab at week 28 and continued a 16-week regimen up to week 60.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the PTI regimen, dosing intervals can be extended in 4-week increments or reduced in 4-week or 8-week increments to a minimum of every 8 weeks, a maximum of every 16 weeks, or maintained based on disease activity assessments at study drug dosing visits.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Archway: monthly monitoring during 24-week refill intervals
“Patients treated with the PDS Q24W were monitored monthly through trial completion to maintain visual acuity examiner masking, and additional safety visits were performed at days 2 and 7 after implantation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Archway required monthly monitoring for PDS-treated patients to align with the visit schedule of the monthly ranibizumab comparator arm.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“the Archway trial was not designed to evaluate the number of visits required for monitoring PDS-treated patients” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Summary
In the phase 3 LUGANO trial (432 participants; vorolanib insert 2.7 mg every 6 months versus aflibercept 2 mg every 8 weeks), the vorolanib insert did not achieve noninferiority for mean change in best-corrected visual acuity at weeks 52 and 56 in the full dataset. An ad hoc analysis excluding 9 of 211 insert-arm participants met the noninferiority criterion (nominal p = 0.0096). Relative to on-label aflibercept, the insert reduced treatment burden by 42% (nominal p < 0.0001), about 2 fewer injections through week 56. Of insert-treated participants, 76% were supplement-free through week 32, 54% through week 56, and 79% received zero or one supplemental injection through week 56. The mean difference in central subfield thickness versus aflibercept was 4 microns at week 56. Rates of cataract, elevated intraocular pressure, and intraocular inflammation did not differ between arms. In the phase 2 DAVIO 2 trial of previously treated participants, the 2 mg and 3 mg doses differed from aflibercept by -0.3 and -0.4 letters, respectively, at weeks 28 and 32, and 65% and 64% of eyes were supplement-free through 6 months. In the identical phase 3 LUCIA trial (475 participants), the vorolanib insert also did not achieve noninferiority: least squares mean BCVA change was +2.5 letters with the insert and +6.1 letters with aflibercept (difference -3.7 letters). Treatment burden was reduced by 38% (nominal p < 0.0001); 52% of insert-treated participants were supplement-free and 71% received zero or one supplemental injection through week 56; and mean central subfield thickness change was -66 µm with the insert and -82 µm with aflibercept (difference +16 µm). All data are topline or preliminary sponsor reports.
LUGANO: topline efficacy outcomes through Week 56
| Outcome | Quoted result |
|---|---|
| Primary endpoint, full dataset | “the primary endpoint of change from baseline in best corrected visual acuity (BCVA) versus 2 mg aflibercept on-label control was not achieved in the full dataset” |
| Treatment burden | “42% reduction in treatment burden, achieving superiority versus on-label aflibercept (nominal p-value<0.0001) compared to a maximum possible reduction of 60%” |
| Injections avoided | “two fewer injections on average in DURAVYU patients versus on-label aflibercept up to Week 56” |
| Supplement-free through Week 32 | “76% of DURAVYU patients were supplement-free up to Week 32” |
| Supplement-free through Week 56 | “54% of DURAVYU patients were supplement-free up to Week 56” |
| Zero or one supplement through Week 56 | “79% of DURAVYU patients received zero or one supplement up to Week 56” |
| Central subfield thickness | “a mean difference of 4 microns versus on-label aflibercept control in central subfield thickness (CST) at Week 56” |
LUGANO: ocular safety compared with aflibercept
LUGANO: visual acuity excluding participants with vision loss unrelated to wet AMD
DAVIO 2: Week 32 outcomes in previously treated participants
DAVIO 2: 12-month supplement-free rate after a single injection
Visual acuity outcomes with extended-interval faricimab and every-8-week aflibercept at week 48
“In the primary analysis (ITT population), adjusted mean gains in BCVA at primary endpoint visits in TENAYA were 5·8 letters (95% CI 4·6 to 7·1) in the faricimab group and 5·1 letters (3·9 to 6·4) in the aflibercept group (treatment difference 0·7 letters [95% CI −1·1 to 2·5]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In LUCERNE, vision gains were 6·6 letters (95% CI 5·3 to 7·8) in the faricimab group and 6·6 letters (5·3 to 7·8) in the aflibercept group (treatment difference 0·0 letters [95% CI –1·7 to 1·8]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In CMH-weighted estimates, 20·0–20·2% of faricimab-treated patients gained 15 or more letters compared with 15·7–22·2% of patients in the aflibercept group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote